Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Neoplasms 2Lung Neoplasms 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Glioblastoma 2Brain Neoplasms 2Adenocarcinoma of Lung 2Urinary Bladder Neoplasms 1Solid Tumor 1Peripheral Nervous System Diseases 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Oligodendroglioma 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1NSCLC 1Myeloproliferative Disorders 1Lymphoma, T-Cell, Cutaneous 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid 1Leukemia 1Hematologic Diseases 1Head and Neck Neoplasms 1Glioma 1Gastrointestinal Stromal Tumors 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

sagopilone 1pembrolizumab 1nabilone 1eribulin 1enfortumab vedotin 1allantoicase 1Prednisolone 1N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid 1Lenalidomide 1Exercise 1Epoetin Alfa 1BID protein, human 1Acetylcarnitine 14-((3-(1,6-dihyro-6-oxo-9H-purin-9-yl)-1-oxopropyl)amino)benzoic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Peripheral Nervous System Diseases × BID protein, human × Clear all
NCT00751205 2014-10-28

Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)

Bayer

Phase 2 Completed
150 enrolled
GenitourinaryGynecologic

Ovarian Neoplasms, Peripheral Nervous System Diseases, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡